Stay updated with breaking news from Presented December. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
New approaches to treating hemophilia may soon replace the decades-old approach of using factor concentrates to control bleeding in patients with hemophilia A and hemophilia B.
Tyrosine kinase inhibitors and novel agents like bi-specific T-cell engager and antibody drug conjugates have diminished the need for chemotherapy in adults with acute lymphoblastic leukemia (ALL).
Set to launch in early 2022, the open-source tool combines study data with artificial intelligence to model incidence, prevalence, burden, and the potential impact of interventions.
'Many nongenetic factors also contribute to differences that we see, including some socioeconomic and other factors that feed into health disparities,' Dr Andrew F. Alexis said.